The full regulatory picture for compounded peptides after the HHS reversal — and what it means for sourcing.
Last updated: March 28, 2026. We will continue to update this article as the FDA publishes formal guidance.
The peptide compounding landscape shifted dramatically in early 2026. After nearly two years of increasingly restrictive FDA enforcement that placed 19 popular peptides on a Category 2 "do not compound" list, HHS Secretary Robert F. Kennedy Jr. announced in late February 2026 that approximately 14 of those peptides would be reclassified back to Category 1 — restoring legal access through licensed compounding pharmacies with a physician's prescription.
For pharmacies, clinics, and practitioners who source peptide APIs, this is the most significant regulatory shift since the original Category 2 designations in late 2023. But the details matter enormously, and much of the reporting on this topic has conflated what was announced with what has actually been finalized.
In late 2023, the FDA reclassified 19 widely used peptides as Category 2 bulk drug substances — a designation reserved for compounds the agency considers to carry significant safety risks. The practical effect was immediate: licensed compounding pharmacies could no longer legally prepare these peptides for patients, even with a valid physician's prescription.
The 19 peptides included some of the most widely prescribed compounds in regenerative medicine and longevity practice: BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, KPV, MOTS-c, GHK-Cu, and others.
The FDA cited concerns over immunogenicity, manufacturing impurities in compounded preparations, and the absence of large-scale human clinical trials. Critics — including clinicians, compounding pharmacy associations, and some members of Congress — argued the move was regulatory overreach that would push patients toward unregulated grey-market sources, creating the exact safety problems the FDA claimed it wanted to prevent.
That argument proved prescient. During the restriction period, the grey market for peptides expanded significantly, with patients sourcing injectable compounds from overseas vendors, "research use only" suppliers, and unregulated online retailers with little or no quality assurance.
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 of the 19 Category 2 peptides would be moved back to Category 1 status. The announcement circulated rapidly through the peptide and wellness communities.
The peptides expected to return to legal compounding status include BPC-157 (tissue repair and gut healing), Thymosin Alpha-1 (immune modulation — already approved in over 30 countries outside the U.S.), TB-500/Thymosin Beta-4 fragment (wound healing and cell migration), AOD-9604 (fat metabolism), CJC-1295 and Ipamorelin (growth hormone releasing peptides), Selank and Semax (neuropeptides), KPV (anti-inflammatory), MOTS-c (mitochondrial/metabolic peptide), and GHK-Cu (tissue remodeling).
Approximately five peptides are expected to remain restricted due to weaker safety profiles or insufficient human data.
As of late March 2026, the formal FDA updated Category list has not been published. The HHS announcement signals the direction of travel, but it does not constitute regulatory action. Until the FDA formally updates its interim policy guidance documents for both 503A and 503B compounding, the legal status of these peptides technically remains unchanged.
This creates an uncomfortable gap for pharmacies and practitioners. The political signal is clear, but the regulatory paperwork hasn't caught up. Pharmacies that resume compounding before formal guidance is published are operating in a legal grey zone — and the ones with the best compliance programs will wait for the official reclassification before changing their formularies.
The FDA uses a three-tier system to evaluate bulk drug substances for compounding eligibility under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act:
| Category | Status | Compounding Eligibility |
|---|---|---|
| Category 1 | Adequate safety and usage data | Can be compounded under 503A/503B with a valid prescription |
| Category 2 | Identified safety concerns or under review | Not currently eligible for routine compounding |
| Category 3 | Determined not suitable for compounding | Compounding prohibited |
Category 2 designation does not mean a substance is formally banned or that the FDA has completed its safety review. It reflects regulatory concern — often about immunogenicity, aggregation risk, sterility in compounded formulations, or insufficient clinical evidence — and places the substance in a holding pattern while evaluation continues.
Demand will spike. The moment formal reclassification happens, patient demand through legitimate pharmacy channels will surge. Pharmacies with established API supplier relationships will be positioned to meet that demand. Those scrambling after the fact will face longer lead times and potentially higher prices.
GMP sourcing becomes non-negotiable. With peptides returning to the regulated pharmacy channel, the standard is pharmaceutical-grade GMP API with full batch documentation. Research-grade material — regardless of purity — doesn't meet compliance requirements for 503A or 503B compounding. Our GMP vs Research Grade guide breaks down exactly what that distinction means.
CoA verification matters more than ever. The grey-market ecosystem that grew during the restriction period produced enormous volumes of questionable Certificates of Analysis — some fabricated, others reused across batches, many from in-house testing with no independent verification. As the market shifts to regulated channels, the quality of your documentation is the quality of your defense during an inspection. See our CoA reading guide.
The GLP-1 situation is separate. FDA-approved GLP-1 receptor agonists like semaglutide and tirzepatide are in a completely different regulatory category. These are fully approved drugs where compounding has been permitted only under specific shortage conditions. The Category 2 reclassification does not affect GLP-1 compounding — that remains governed by the drug shortage list and active litigation from brand manufacturers.
The legality of the FDA's original Category 2 designations has been challenged in court. Compounding pharmacy groups argued the agency bypassed required notice-and-comment rulemaking by implementing what amounted to a compounding ban through interim guidance documents rather than formal regulation. In at least one case, the FDA acknowledged procedural shortcomings in settlement.
Critics have also raised questions about whether the FDA overstepped its statutory authority under the Drug Quality and Security Act of 2013, which was intended to give the agency a complementary oversight role — not the power to unilaterally ban entire classes of therapies that licensed providers had been safely compounding for years.
This legal backdrop is part of what made the political reversal possible: the enforcement was on shaky procedural ground to begin with.
Don't source from grey-market vendors. The reclassification timeline is measured in weeks. Sourcing from unregulated suppliers now — when legitimate pharmacy-grade options are about to become available — creates compliance risk for very little gain.
Start vetting GMP API suppliers now. The best time to qualify your peptide supply chain is before you need product urgently. Review certificates, request facility documentation, and build relationships with manufacturers who can provide full GMP batch records. Our supplier evaluation guide walks through this process step by step.
Monitor FDA publications. The change is not final until updated guidance documents are published. Watch the FDA's compounding page for updates.
Document everything. When you begin sourcing reclassified peptides, maintain impeccable records — GMP certificates, batch-matched CoAs, supplier qualification files, and prescriber orders. This is what protects you during an inspection.